NEW YORK and HERZLIYA, Israel — March 3, 2026 — Leads & Copy — InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) has received a notice from the Nasdaq Stock Market LLC indicating non-compliance with Nasdaq Listing Rule 5450(a)(2), as the company’s closing bid price for its ordinary shares was below $1.00 for the last 30 consecutive business days.
According to Nasdaq Listing Rule 5810(c)(3)(A), InterCure has been granted a 180-calendar day compliance period, until August 24, 2026, to regain compliance. To achieve this, the closing bid price of the Ordinary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during this period.
If the company fails to comply by August 24, 2026, it anticipates being eligible for an additional 180-calendar day compliance period. To qualify, InterCure must submit a transfer application, meet the continued listing requirement for market value of publicly held shares, and fulfill all other initial listing standards for the Nasdaq Capital Market, excluding the minimum bid price requirement. The company must also provide written notice of its intention to address the deficiency during this extended period.
InterCure intends to monitor the closing price of its Ordinary Shares and consider a reverse share split, pending corporate and regulatory approvals. The company believes this measure, along with its ongoing business and strategic initiatives, will help restore compliance within the applicable timeframe. The company’s Ordinary Shares will continue to be listed and trade on the Nasdaq Global Market during this period.
If InterCure does not regain compliance within the allotted time, including any extensions granted by Nasdaq, the company will receive a notice indicating its Ordinary Shares are subject to delisting.
This announcement complies with Nasdaq Listing Rule 5810(b), which mandates prompt disclosure of deficiency notifications.
InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is described as a leading, profitable, and fast-growing cannabis company outside of North America. Its subsidiary, Canndoc, is Israel’s largest licensed cannabis producer, offering Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. The company utilizes its distribution network, international partnerships, and a vertically integrated “seed-to-sale” model.
Source: InterCure
